Douglas F. Kling net worth and biography

Douglas Kling Biography and Net Worth

Douglas Kling joined NewAmsterdam Pharma in March 2021 as Chief Operating Officer. Previously, he was Senior Vice President of Clinical Operations at Corvidia Therapeutics, which sold to Novo Nordisk in July 2020. At Corvidia, Douglas managed the clinical development of ziltivekimab, an anti-IL6 monoclonal antibody, being developed to treat cardiovascular disease in patients with chronic kidney disease. Douglas is an expert in the development of drugs to treat dyslipidemia and cardiovascular disease. Prior to Corvidia, Douglas was the Senior Vice President of Clinical Development & Project Management at Omthera Pharmaceuticals, which sold to AstraZeneca Pharmaceuticals in 2013. Douglas also worked at the Medicines Company and Reliant Pharmaceuticals, managing the development activities for various drugs in the dyslipidemia and cardiovascular space. Douglas earned a BS from Duke University and an MBA from Rutgers Business School.

What is Douglas F. Kling's net worth?: The estimated net worth of Douglas F. Kling is at least $1.58 million as of July 15th, 2025. Mr. Kling owns 44,000 shares of NewAmsterdam Pharma stock worth more than $1,577,400 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Kling may own. Learn More about Douglas F. Kling's net worth.
How old is Douglas F. Kling?: Mr. Kling is currently 51 years old. There are 6 older executives and no younger executives at NewAmsterdam Pharma. The oldest executive at NewAmsterdam Pharma is Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director, who is 70 years old. Learn More on Douglas F. Kling's age.
How do I contact Douglas F. Kling?: The corporate mailing address for Mr. Kling and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at [email protected]. Learn More on Douglas F. Kling's contact information.
Has Douglas F. Kling been buying or selling shares of NewAmsterdam Pharma?: Douglas F. Kling has not been actively trading shares of NewAmsterdam Pharma during the last quarter. Most recently, Douglas F. Kling sold 51,043 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a transaction totalling $1,077,007.30. Following the completion of the sale, the chief operating officer now directly owns 44,000 shares of the company's stock, valued at $928,400. Learn More on Douglas F. Kling's trading history.
Who are NewAmsterdam Pharma's active insiders?: NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Douglas Kling (COO), Louise Kooij (CAO), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.
Are insiders buying or selling shares of NewAmsterdam Pharma?: During the last twelve months, NewAmsterdam Pharma insiders bought shares 8 times. They purchased a total of 19,895 shares worth more than $404,974.43. During the last twelve months, insiders at the sold shares 14 times. They sold a total of 979,881 shares worth more than $23,220,192.76. The most recent insider tranaction occured on September, 15th when Director James N Topper bought 660 shares worth more than $15,642.00. Insiders at NewAmsterdam Pharma own 20.8% of the company. Learn More about insider trades at NewAmsterdam Pharma.
Information on this page was last updated on 9/15/2025.

Douglas F. Kling Insider Trading History at NewAmsterdam Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/16/2025	Sell	51,043	$21.10	$1,077,007.30	44,000
7/15/2025	Sell	47,569	$21.44	$1,019,879.36	44,000
6/16/2025	Sell	100,000	$19.29	$1,929,000.00	44,000

Douglas F. Kling Buying and Selling Activity at NewAmsterdam Pharma

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Today's Range

Now: $35.85

$34.99

$36.60

50 Day Range

MA: $36.39

$27.52

$41.45

2 Week Range

Now: $35.85

$14.06

$42.00

Volume

1,788,591 shs

Average Volume

1,012,409 shs

Market Capitalization

$4.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Douglas Kling Biography and Net Worth

What is Douglas F. Kling's net worth?

How old is Douglas F. Kling?

How do I contact Douglas F. Kling?

Has Douglas F. Kling been buying or selling shares of NewAmsterdam Pharma?

Who are NewAmsterdam Pharma's active insiders?

Are insiders buying or selling shares of NewAmsterdam Pharma?